Patent ID: 8048883

Claim:
An α 2 crystalline form of Imatinib Mesylate which has the XRPD characteristics given below Angle d Value Intensity % 2-Theta Angstrom % 4.841 18.24057 33.6 10.410 8.49070 100.0 11.194 7.89775 14.2 11.856 7.45827 19.9 12.881 6.86709 6.8 13.819 6.40328 12.9 14.860 5.95663 67.7 16.439 5.38788 32.4 17.049 5.19665 5.6 17.623 5.02870 58.6 18.052 4.91000 61.6 18.567 4.77491 98.8 19.032 4.65925 70.2 19.772 4.48657 15.3 21.236 4.18055 60.8 21.582 4.11431 59.4 22.594 3.93217 19.7 23.137 3.84112 21.8 23.696 3.75172 25.0 24.851 3.57993 58.6 26.250 3.39226 9.1 27.341 3.25932 18.7 28.475 3.13204 42.4 31.896 2.80347 9.0 32.533 2.75005 6.6 43.447 2.08117 6.4 which is sufficiently stable that it retains these XRPD characteristics after 6 hours at 120° C. and/or after 6 months at about 40° C. and about 75% relative humidity; and which is a solid in the form of free flowing crystals that are not needle shaped.